EN DE
Watch NGeneBio Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NGeneBio Co. Ltd. (354200) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of NGeneBio Co. Ltd. stock KRW 637, price KRW 741, that is 14.0% below the price, quality 30 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

NC NGeneBio Co. Ltd. logo Thin data Nov 4, 2026

NGeneBio Co. Ltd.

354200 · KQ
Expensive, weak quality

Our calculation puts a fair price 14% below what the stock costs today.

Low debt
Ranks above peers (6/10)
Expensive Growth (revenue 5y +53.7 %/yr in KRW)
Fair value 637.36 KRW · Overvalued
Quality 30/100
Loss-making · -12.1% net margin (TTM)
Negative free cash flow
Narrow moat 5/100 · thin data
Thin data
⚠ Dilution
Watch NGeneBio Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

59,826 KRW 619.00 KRW Fair Value 637.36 KRW May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 619.00 KRW – 59,826 KRW · fair‑value band 475.63 KRW – 951.28 KRW · the 741.00 KRW price screens above the 637.36 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow NGeneBio Co. in your weekly email

Every Wednesday you see whether NGeneBio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software.

Show moreShow less

It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test.

The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS. In addition, it offers MTBaccuPanel, a diagnostic panel to test mycobacterium tuberculosis, identification of nontuberculous mycobacteria species, and detection of mutations associated with drug resistance; and NGenePlex nCoV qRT-PCR Kit, a reagent of real-time reverse transcription-polymerase chain reaction assay intended for the qualitatively detecting nucleic acid of SARS-CoV-2 from patients infected or suspected of COVID-19. The company was incorporated in 2015 and is headquartered in Seoul, South Korea.

Stock analysis

NGeneBio Co. Ltd. (354200) currently trades at 741.00 KRW, while our model-based Fair Value estimate is 637.36 KRW, 14% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 475.63 KRW (bear) to 951.28 KRW (bull), the price of 741.00 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

NGeneBio Co. Ltd. reported revenue of 21.2B KRW in FY2025 versus 7.2B KRW in FY2021, a compound +31.2%/yr. Reported net income was −5.5B KRW in FY2025.

Key figures

Market cap 18.6B KRW (≈ $13.7M) Micro · P/S ratio 0.25 · EPS (TTM) −288.32 KRW · Net margin −26.1% · Return on equity −26.8% · Return on assets (EBIT) −25.4% (5-year average) · Operating margin −9.5% · Revenue (TTM) 41.8B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 89% below its 52-week high and 20% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −14%, 354200 screens richer than that median.

Fair Value models

Bear 475.63 KRW Fair Value 637.36 KRW Bull 951.28 KRW
Price 741.00 KRW · Downside -14.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 559.57 KRW 749.83 KRW 1,119 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 559.57 KRW 749.83 KRW 1,119 KRW 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 23
Do the profits arrive as real cash?
Financial strength 19
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+273.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−246.2% (2020) → −39.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

354200 screens overvalued: fair value 14% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare NGeneBio Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −14.0% · Above median
Profitability
Return on assets −7.7% · Above median
Net margin (12 months) −12.1% · Below median
Operating margin (12 months) −9.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 573.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.81× · Cheapest 25%
P/S (12 months) 0.44× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 354200
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 354200
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 354200
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 354200
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 354200
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 354200
argenx SE ARGX $927.21 $908.40 −2% vs 354200
CSL Limited CSL A$200.77 A$183.04 −9% vs 354200
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 354200
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 354200

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NGeneBio Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NGeneBio Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/354200

Frequently asked questions

Is NGeneBio Co. Ltd. (354200) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 637.36 KRW versus a price of 741.00 KRW, about 14% lower (overvalued).
What is the fair value of 354200?
Our model-based fair value for NGeneBio Co. Ltd. is 637.36 KRW (as of Nov 4, 2026), built from audited fundamentals. The current price: 741.00 KRW.
What is the quality score of 354200?
NGeneBio Co. Ltd. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NGeneBio Co. Ltd. (354200)?
Our model-based price target is the fair value of 637.36 KRW (as of Nov 4, 2026) from 1 valuation models. Cautious scenario 475.63 KRW, optimistic scenario 951.28 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the NGeneBio Co. Ltd. stock forecast for 2026?
Our models put fair value at 637.36 KRW, about 14% lower versus a price of 741.00 KRW (overvalued). Cautious scenario 475.63 KRW, optimistic scenario 951.28 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NGeneBio Co. Ltd. (354200)?
NGeneBio Co. Ltd. reported trailing-twelve-month revenue of about 41.8B KRW (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of NGeneBio Co. Ltd. (354200)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NGeneBio Co. Ltd. it is 637.36 KRW per share (as of Nov 4, 2026), against a price of 741.00 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is NGeneBio Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 354200 trades above its calculated fair value: price 741.00 KRW, fair value 637.36 KRW, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 354200?
No. The price is what the market pays today (741.00 KRW); the fair value is what the company's own numbers justify (637.36 KRW). For NGeneBio Co. Ltd. the two are 103.64 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NGeneBio Co. Ltd. worth?
The market values NGeneBio Co. Ltd. at about 18.6B KRW (market capitalisation, as of Nov 4, 2026). Per share that is 741.00 KRW; our models calculate a fair value of 637.36 KRW per share.
What do the bullish and bearish scenarios say about 354200?
Our models span a range for NGeneBio Co. Ltd.: cautious scenario 475.63 KRW, base 637.36 KRW, optimistic 951.28 KRW per share (as of Nov 4, 2026, price 741.00 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NGeneBio Co. Ltd. (354200)?
Balance-sheet figures for NGeneBio Co. Ltd. (as of Nov 4, 2026): return on equity −26.8%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 354200 from its 52-week high?
NGeneBio Co. Ltd. trades at 741.00 KRW, about 89% below its 52-week high of 6,652 KRW and 20% above the low of 619.00 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 637.36 KRW is for.
Which stocks are comparable to NGeneBio Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NGeneBio Co. Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 741.00 KRW, calculated fair value 637.36 KRW (−14%), Quality Score 30/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 354200 calculated?
We run NGeneBio Co. Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 637.36 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NGeneBio Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NGeneBio Co. Ltd. (354200)?
The closing price on Nov 6, 2026 was 741.00 KRW. Our model-based fair value is 637.36 KRW, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NGeneBio Co. Ltd. right now?
A fairly wide model range (475.63 KRW to 951.28 KRW) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NGeneBio Co. Ltd.

How large is the market capitalisation of NGeneBio Co. Ltd. (354200)?
The market capitalisation of NGeneBio Co. Ltd. is 18.6B KRW (≈ $13.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NGeneBio Co. Ltd. (354200)?
The price-to-sales ratio of NGeneBio Co. Ltd. is 0.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NGeneBio Co. Ltd. (354200)?
Earnings per share at NGeneBio Co. Ltd. are −288.32 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NGeneBio Co. Ltd. (354200)?
The net margin of NGeneBio Co. Ltd. is −26.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NGeneBio Co. Ltd. (354200)?
The return on equity (ROE) of NGeneBio Co. Ltd. is −26.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NGeneBio Co. Ltd. (354200)?
On an EBIT basis the return on assets of NGeneBio Co. Ltd. is −25.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NGeneBio Co. Ltd. (354200)?
The operating margin of NGeneBio Co. Ltd. is −9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NGeneBio Co. Ltd. (354200)?
Revenue at NGeneBio Co. Ltd. is growing +574% versus a year earlier (3y avg +24.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NGeneBio Co. Ltd. (354200) generate?
The free cash flow of NGeneBio Co. Ltd. is −8.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does NGeneBio Co. Ltd. (354200) carry?
The net debt of NGeneBio Co. Ltd. is 30.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch NGeneBio Co. Ltd. in the live analysis

One click puts NGeneBio Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.